Editorial: One small step for metaplasia, but one giant leap for biomarkers is needed

American Journal of Gastroenterology

Volumn 104, Issue 11, 2009, Pages 2681-2683

  Nicholson, Anna ^a   Jankowski, Janusz ^a,b,c  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b UNIVERSITY HOSPITALS OF LEICESTER NHS TRUST   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BIOLOGICAL MARKER; ESOMEPRAZOLE;

BARRETT ESOPHAGUS; CHEMOPROPHYLAXIS; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGUS BIOPSY; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; MOLECULAR CLONING; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW;

ADENOCARCINOMA; BARRETT ESOPHAGUS; CELL TRANSFORMATION, NEOPLASTIC; DISEASE PROGRESSION; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; MALE; METAPLASIA; NEEDS ASSESSMENT; PRECANCEROUS CONDITIONS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 72049121208     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2009.450     Document Type: Review

References (19)

1. Lagergren J. Adenocarcinoma of oesophagus: what exactly is the size of the problem and who is at risk? Gut 2005;54 (Suppl 1):i1-5.
2. Moayyedi P , Burch N , Akhtar-Danesh N et al. Mortality rates in patients with Barrett's oesophagus. Aliment Pharmacol Th er 2008;27:316-320
3. Galipeau PC , Prevo LJ , Sanchez CA et al. Clonal expansion and loss of heterozygosity at chromosomes 9p and 17p in premalignant esophageal (Barrett's) tissue. J Natl Cancer Inst 1999;91:2087-2095
4. Wong DJ , Paulson TG , Prevo LJ et al. p16(INK4a) lesions are common, early abnormalities that undergo clonal expansion in Barrett's metaplastic epithelium. Cancer Res 2001;61:8284-8289
5. Bani-Hani K , Martin IG , Hardie LJ et al. Prospective study of cyclin D1 overexpression in Barrett's esophagus: association with increased risk of adenocarcinoma. J Natl Cancer Inst 2000;92:1316-1321 (Pubitemid 30660591)
6. Lao-Sirieix P , Lovat L , Fitzgerald RC. Cyclin A immunocytology as a risk stratifi cation tool for Barrett's esophagus surveillance. Clin Cancer Res 2007;13 (2 Pt 1):659-665 (Pubitemid 46225374)
7. Schulmann K , Sterian A , Berki A e t al. Inactivation of p16, RUNX3, and HPP1 occurs early in Barrett's-associated neoplastic progression and predicts progression risk. Oncogene 2005;24:4138-4148
8. Sirieix PS , O ' Donovan M , Brown J et al. Surface expression of minichromosome maintenance proteins provides a novel method for detecting patients at risk for developing adenocarcinoma in Barrett's esophagus. Clin Cancer Res 2003;9:2560-2566 (Pubitemid 36842097)
9. Sikkema M. Aneuploidy and overexpression of Ki67 and p53 as markers for neoplastic progression in Barrett esophagus: a case control study. Am J Gastroenterol 2009;104:2673-2680 (this issue).
10. Jankowski JA , Odze RD. Biomarkers in gastroenterology: between hope and hype comes histopathology. Am J Gastroenterol 2009;104:1093-1096
11. Attwood SE , Harrison LA , Preston SL et al. Esophageal adenocarcinoma in " mice and men ": back to basics!. Am J Gastroenterol 2008;103:2367-2372
12. Ioannidis JP , Trikalinos TA , Ntzani EE et al. Genetic associations in large versus small studies: an empirical assessment. Lancet 2003;361 : 567-571
13. Jankowski J , McMenemin R , Hopwood D e t al. Abnormal expression of growth regulatory factors in Barrett's oesophagus. Clin Sci (Lond) 1991;81:663-668
14. Jankowski JA , Harrison RF , Perry I et al. Barrett's metaplasia. Lancet 2000;356:2079-2085
15. Jankowski JA , Wright NA , Meltzer SJ et al. Molecular evolution of the metaplasia- dysplasia-adenocarcinoma sequence in the esophagus. Am J Pathol 1999;154:965-973
16. Leedham SJ , Preston SL , McDonald SA et al. Individual crypt genetic heterogeneity and the origin of metaplastic glandular epithelium in human Barrett's oesophagus. Gut 2008;57:1041-1048
17. Kariv R , Plesec TP , Goldblum JR et al. Th e Seattle protocol does not more reliably predict the detection of cancer at the time of esophagectomy than a less intensive surveillance protocol. Clin Gastroenterol Hepatol 2009;7:653-8;quiz 606.
18. Das D , Chilton AP , Jankowski JA. Chemoprevention of oesophageal cancer and the AspECT trial. Recent Results Cancer Res 2009;181:161-169
19. Shaheen NJ , Sharma P , Overholt BF et al. Radiofrequency ablation in Barrett's esophagus with dysplasia. N Engl J Med 2009;360:2277-2288